Home Tags Linker chemistry

Tag: linker chemistry

A new technology enables a simple way of connecting the cytsteine residues (SH) of a tumor-sensing antibody (yellow) to the cytotoxic payload. The emerging linker is highly stable during blood circulation and enables therefore a safe transport to the tumor side. Image courtesy: Barth van Rossum/FMP

A Superglue for ADCs: Connecting the Cytsteine Residues of a Tumor-sensing...

The Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) and the Ludwig-Maximilians-Universität München (LMU) hve developed an innovative technology designed to make it possible to treat cancer...

YProtech: Specialists in High Value Chemistries, from Early Research and Lead...

Established in 2011 YProtech is a leading Chemistry Services Contract Research Organization specializing in high value chemistry services. The company offers niche chemistry based services...
Manufacturing

Antibody Drug Conjugate Development: Keys to Rapid IND Submission and Approval

Antibody drug conjugates (ADCs) are a relatively new type of drug that combines the targeting ability of a biologic with a highly potent cytotoxic...

Preclinical Studies Show Significant Improved Therapeutic Index

Synaffix, a Netherlands-based biotechnology company exclusively focusing on the continued advancement of best-in-class and industry leading antibody-drug conjugate (ADC) technology platforms, has competed a new set...

Avacta and Glythera Partner to Develop Novel, Highly Targeted, Drugs

Avacta Life Sciences, the developer of Affimer® biotherapeutics and research reagents will collaborate with Glythera a developer of advanced, stable conjugation chemistries and novel, ultra-potent...

Linkers for Antibody Drug Conjugates: Current Role and Advancements

Advancements in research have shifted the way we think of combating cancer, and traditional treatment options are on the path to being replaced by...

Kairos and Zymeworks Bring Together Complementary Technologies for the Development of...

Zymeworks, a privately held biotherapeutics company developing best-in-class Azymetric™ bi-specific antibodies, multi-specific antibodies and antibody drug conjugates for the treatment of cancer, and Kairos Therapeutics,...

FEATURED RESOURCES